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ABSTRACT
Background:
Hyperbilirubinemia is a common problem in newborn infants. It can progress to kernicterus
in severe forms, unless an intervention is initiated. The objective of this study was to compare
the efficacy of Clofibrate with Phenobarbital in full-term neonates with nonhemolytic jaundice.
Methods:
this double blind clinical trial study was performed on 60 neonate who were divided
randomly in two groups of full-term jaundiced neonates: the clofibrate-treated group (n = 30)
and the Phenobarbital group (n = 30). Infants in the clofibrate group received a single oral dose
of 100 mg.kg clofibrate while the neonates in the Phenobarbital group received a single oral
dose of 5 mg.kg Phenobarbital; both groups received phototherapy. Total serum and direct
bilirubin levels were measured at the beginning, 12 and 24 hours after the initiation of
treatment.
Results:
The mean ± SD total serum bilirubin level of the Phenobarbital group and clofibrate groups
at enrollment was 17.84 ± 1.017 and 18.04 ±0.852 mg.dL, respectively. The mean ± SD total
serum bilirubin in Phenobarbital group and clofibrate groups after 24 hours was 11.11 ± 1.273
and 12.55 ± 1.008 mg.dL, respectively (P = 0.000). After 72 hours of intervention, 25 (83%)
neonates of the Phenobarbital group and 23 (76%) of the clofibrate group were discharged with
a total serum bilirubin of <10 mg.dL (P = 0.000). No side-effect was observed on serial
examination during hospitalization, and on the first and seventh day after discharge.
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Conclusion:
Phenobarbital in the compared with clofibrate results in a faster decline in total serum
bilirubin, shorter duration of hospitalization and had no side effects in jaundiced full-term
neonates.
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Introduction
Hyperbilirubinemia is the most common
medical problem during neonatal period;
about sixty percent of full term neonates
develop non-hemolytic hyperbilirubinemia.
About six to ten percent of newborn infants
suffer from severe hyperbilirubinemia,
which must be treated (amount of serum
bilirubin is above the 90% percentile for
age) (2, 3). Moreover, hyperbilirubinemia
is the most common cause of re-
hospitalization during the neonatal period
(4, 5). On the other hand, one of the serious
complications of severe indirect
hyperbilirubinemia is its toxic effect on
central nervous system (CNS), which
causes mental retardation and physical
disability (6-8). The therapeutic goal of
neonatal hyperbilirubinemia is prevention
of CNS toxicity of indirect bilirubin (6, 9).
Phototherapy and exchange transfusion are
used as common methods for treatment of
indirect hyperbilirubinemia. However
exchange transfusion and phototherapy are
costly for families. In addition in these
methods, the infant is limited into the
incubator, so the relationship between the
mother and infant is interrupted. Infection,
dehydration and neonatal death are some of
disadvantages of exchange transfusion (10,
11). Moreover, several studies have shown
that when total serum bilirubin level passes
more than 20 mg.dl; the efficacy of
phototherapy will be reduced about 10-17%
(12). Pharmaceutical agents that have been
suggested for this purpose are
Metalopurphyrins, intravenous
immunoglobulin and Phenobarbital (13-
16).  Clofibrate is a proxisome proliferator-
activated receptors (PPAR) agent, so it
influences on lipid metabolism and reduces
the serum level of cholesterol and
triglycerides. This medication has been
used for reducing of serum lipids in adults
for years (17, 18). It can also increase the
amount of conjugation and excretion of
bilirubin in the liver (19) and therefore has
been suggested for treatment of
hyperbilirubinemia (20). Side effects such
as nausea, vomiting, gastrointestinal
disturbances and watery stool have been
reported duo to consumption of this drug.
The use of a single dose of 100 mg per kg
of body weight of Clofibrate for infants that
suffering hyperbilirubinemia has no side
effect. Phenobarbital is known as an
anticonvulsant drug but it has some another
applications. It is the drug of choice for
treatment of autosomal dominant Crigler–
Najjar syndrome (type II). It functions as an
enzyme-inducer for glucuronosyl
transferase and therefore increases its
efficacy. In addition, Phenobarbital reduces
the level of serum indirect bilirubin by
increasing of its excretion from the liver
(21). Common side effects of this drug are
nausea, vomiting, skin eruptions and
drowsiness. Clofibrate and Phenobarbital
both can be used with some safety in
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neonates. On the other hand, there is
confusion about an effective drug for
treatment of neonatal hyperbilirubinemia.
In this study, we have compared the
efficacy of Phenobarbital with Clofibrate in
treatment of neonatal hyperbilirubinemia.
Materials and Methods
This study is a double blind randomized
clinical trial that was carried out in neonatal
ward of Sabalan hospital in Ardabil in
1388. Full term neonates (gestational age
between 38-42 weeks) with non-hemolytic
hyperbilirubinemia (a total serum bilirubin
of 16-25 mg.dl) without any infection or
other abnormalities were included in this
study. Exclusion criteria were neonates
with sepsis, body weight more than 4 or less
than 2 kg, cardiopulmonary problems,
extensive scalp hematoma, G6PD
deficiency, hemolytic hyperbilirubinemia,
direct bilirubin more than 2 mg.dl (or more
than 20% of total serum bilirubin), total
serum bilirubin less than 16 or more than 25
mg.dl. Neonates that fulfilled inclusion
criteria were divided into two groups. Both
groups were inclusive of 30 neonates: the
first group were treated with Clofibrate plus
phototherapy and the second group with
Phenobarbital plus phototherapy. Division
of samples in these two groups was
accidental. In the first group, Clofibrate was
prescribed as pearl tablet with a dose of 100
mg per kilogram of body weight. In the
second group, Phenobarbital was
prescribed as tablet with a dose of 5 mg per
kilogram of body weight. Blood group and
Rh of both mother and neonate, direct
coombs test, peripheral blood smear and
G6PD were studied in both groups. The
amount of total serum bilirubin and
hematocrit of patients were documented on
admission and again 12 and 24 hours
thereafter. Measuring of serum bilirubin
had been continued till the bilirubin level
dropped back to 10 mg.dl. The laboratory
personnel’s had been blinded regarding the
samples. The patients were monitored for
side effects of the drugs including diarrhea,
skin rashes and dehydration during
hospitalization and for 72 hours after that.
Collected data were analyzed by SPSS
software. In both groups, changes in total
serum bilirubin level were evaluated on
admission and 12 and 24 hours after that,
separately. The differences were
considered significant if the P-value was
less than 0.05.
Results
Sixty neonates were included in this
study that females comprised a slightly
higher percentage (56.6% versus 43.3 %).
Sex distribution in Clofibrate group was 16
females and 14 males and in Phenobarbital
group were 18 females and 12 males. The
age ranges of neonates in the Phenobarbital
group were 3 days and 19 days, respectively
with the mean of age of 6.03±2.08 days.
The age range of infants in Clofibrate group
was 3 days and 18 days, respectively. The
mean of age of patients in this group was
2.09± 6.01. Statistically, the mean age of
two groups had no significant difference. In
both groups, 29 patients were RH+ and one
patient was RH- which showed no
significant statistical differences between
two groups. The range of body weight of
patients in both groups was between 2500
and 4000 grams. Therefore there was no
significant difference between the mean
body weights of two groups.
The level of total serum bilirubin during
the first hour of hospitalization was
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18.04±0.852 mg.dl in Clofibrate group and
17.84±1.17mg.dl in Phenobarbital The total
serum bilirubin level 12 hours after onset of
treatment in Clofibrate group was
14.51±1.015 mg.dl and13.44±1.037mg.dl
(P-value<0.05) in Phenobarbital group The
decreasing rate of bilirubin in the first 24
hours of admission was 0.28 mg.dl.h in
Clofibrate group and 0.22 mg.dl.h in
Phenobarbital group. It reveals that
bilirubin decreases with a greater slope in
first 24 hour of admission in Clofibrate
group compared to Phenobarbital group.. In
regard to hospitalization days, 20% of
infants in the phenobarbital group were
hospitalized for two days under
phototherapy while no infant in the
Clofibrate group was hospitalized less than
72 hours. In the phenobarbital group,
63.3% of infants confined to bed for 72
hours and less under phototherapy; 16.7%
confined to bed for 94 hours and less under
phototherapy. Meanwhile, in the Clofibrate
group 76.7 % of infants were confined for
72 hours and 23.3% of them confined for 96
hours as well as under phototherapy. In
average, the hospitalization time in the
phenobarbital group was 2.9 days and 3.2
days in the Clofibrate group (graph 1).
Discussion and conclusion
This study investigated the effect of two
different remedies for the non-hymolytic
hyperbilirubenia in full-term infants.
Bilirubin was examined in the routine hours
of zero, 12 and 24 of phototherapy. The
addition of Phenobarbital to the remedy in
hours 12 and 24 led to a significant
difference (P= 0.001) in decreasing
bilirubin for the Phenobarbital group
(13.44±1.037) compared to the Clofibrate
group ( ١٫٠١۵±١۴٫۵١ ). It seemed that
addition of Phenobarbital to phototherapy
had a better effect on treatment of
hyperbilirubenia. This result is consistant
with Kumar. Et al on preventing effect of
phenobarbital on infants under 1500 grams
(22). In another study, 80 infants with non-
hemolytic hyperbilirubinemia were divided
to two groups of 40 in which the
Phenobarbital group received 3 milligrams
per body weight and the other group
received only phototherapy. On the third
day, significant changes was observed in
the Phenobarbital group compared to the
phototherapy group while duration of
hospitalization was the same (23). In
consistence to our study, the length of
hospitalization in the phenobarbital
recipients compared to the Clofibrate group
was significantly reduced. Caballero-
Noguez et al studied 30 infants affected
with indirect hemolytic hyperbilirubenia in
a randomized clinical trial at their first
week of life. These infants were randomly
divided into three groups. The first group
received phenobarbital, the second group
received Clofibrate and the third group
received placebo. All the groups also
received phototherapy. Their total and
indirect bilirubin was measured at the start
of the trial, 24 and 72 hours later. The
amount of bilirubin in the Phenobarbital
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and the Clofibrate was significantly
reduced at 48 and 72 hours compared to the
placebo group (24). In a study by
Zahedpasha et al done on two groups of
thirty full-term infants affected with
jaundice, the infants who received 100
milligrams per body weight of single dose
of Clofibrate had their bilirubin serum level
reduced after 48 hours. Seventy-two hours
later, 83% of Clofibrate group and 53% of
the control group were released with
bilirubin level of less than 10 mg.dl (1). In
a cohort study done by Miloni and his
colleagues on 66 infants with the G6PD
deficiency showed that 7 milligrams per
infant body weight of phenobarbital
reduces the need for blood transfusion from
33% down to 6% (25). Our study differs
from other studies mentioned for number of
reasons. First, a lower dose of
Phenobarbital was prescribed to avoid
some side effects such as drowsiness and
mother-child communication interruption
(26). Secondly, in our study the effect of
two regimens in reducing the serum level of
hyperbilirubenia of non-hemolytic full-
term infants was compared.In contrast,most
previous studies compared the
effectiveness of these medications and
phototherapy or placebo (1, 22, 24). In the
study of Moslehi et al, they compared the
effects of different small doses of
Clofibrate (25 milligrams per kilogram
body weight). They resulted that Clofibrate
is better in increasing production of
glucuronosyl transferase and causes the
100% increase of bilirubin clearance in the
liver over 6 hours (27). This study is in
discrepancy with our study regarding the
time for onset of bilirubin reduction. In
another study, Zahedpasha et al presented
that Clofibrate like the previous studies
caused the reduction of bilirubin in infants.
The only difference of their study was the
starting time of the administration to the
effect. One of the possible reasons could be
the different rate of the medication
metabolism in human body as well as
different background ethnicities (1). In
accordance to the previous studies, we
documented the reducing effects of
Clofibrate and Phenobarbital in the blood
bilirubin of infants with hyperbilirubenia.
In conclusion, phenobarbital with
phototherapy causes higher and faster
reduction of bilirubin in 24 hours that
continues up to 48 hours compared to
Clofibrate with phototherapy. It also causes
lesser hospital stay.
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